So far, the clinical use of JAK1/2 inhibitors is approved in patients suffering from myelofibrosis and rheumatoid arthritis and they are currently in the clinical development targeting several indications such as graft-versus-host-disease, pancreatic cancer, and myeloproliferative diseases (75). Here, JAK1 is linked to myelofibrosis.